ERBB2 and breast carcinoma: Interestingly, a recent meta-analysis that was carried out on a large set of studies provided clear evidence that patients with a pathological complete response after neoadjuvant chemotherapy displayed a significantly better event-free survival and overall survival, particularly for TNBC and HER2-positive breast cancers; importantly, this association was similar among patients who received, or not, subsequent adjuvant chemotherapy [524].